# A Study of LY3006072 in Healthy Participants

> **NCT01640249** · PHASE1 · TERMINATED · sponsor: **Eli Lilly and Company** · enrollment: 18 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Placebo
- **DRUG:** LY3006072

## Key facts

- **NCT ID:** NCT01640249
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-07-24
- **Primary completion:** 2012-11-26
- **Final completion:** 2012-11-26
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** Study terminated due to unacceptable pharmacokinetic (PK) profile.
- **Last updated:** 2019-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01640249

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01640249, "A Study of LY3006072 in Healthy Participants". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01640249. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*